LIC are protected from conventional chemotherapy by their BM microenvironment and we have previously shown that CD34+ LIC in FLT3-ITD AML persist and expand during treatment with first- and second generation TKI owing to their selective protection by stromal cells [9]. The gene discussed is CD34; the disease is acute myeloid leukemia.